Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nippon Shinyaku CoTSE:4516 +0.75%79 EV-to-EBITDA is 3.77 as of Aug. 17, 2026, which is 75% below its 10-year median of 14.89. GuruFocus rates TSE:4516 with a GF Score™ of 79/100 and a GF Value™ of 円4,635.96 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 734 Drug Manufacturers companies, Nippon Shinyaku Co ranks better than 92.51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nippon Shinyaku Co's enterprise value is 円173,091 Mil.
Nippon Shinyaku Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was 円45,891 Mil. Therefore, Nippon Shinyaku Co's EV-to-EBITDA for today is 3.77.
The historical rank and industry rank for Nippon Shinyaku Co's EV-to-EBITDA or its related term are showing as below:
TSE:4516'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.41 Med: 14.89 Max: 40.68
Current: 3.77
During the past 13 years, the highest EV-to-EBITDA of Nippon Shinyaku Co was 40.68. The lowest was 3.41. And the median was 14.89.
TSE:4516's EV-to-EBITDA is ranked better than 92.51% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.325
vs TSE:4516: 3.77
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nippon Shinyaku Co (TSE:4516) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nippon Shinyaku Co's PE Ratio (TTM) for today is calculated as:
Nippon Shinyaku Co's share price for today is 円3640.00.
Nippon Shinyaku Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円468.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Nippon Shinyaku Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nippon Shinyaku Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nippon Shinyaku Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nippon Shinyaku Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nippon Shinyaku Co's EV-to-EBITDA falls into.
Nippon Shinyaku Co's current Enterprise Value is 円173,091 Mil.
Nippon Shinyaku Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円45,891 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nippon Shinyaku Co (TSE:4516) has a EV-to-EBITDA of 3.77 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nippon Shinyaku Co. This is 75% below median its historical median of 14.89. Over the past decade, Nippon Shinyaku Co's EV-to-EBITDA has ranged from 3.41 to 40.68. According to the industry distribution chart, Nippon Shinyaku Co ranks #55 out of 734 companies in the Drug Manufacturers industry, placing it in the top 7.5%.
Is Nippon Shinyaku Co's EV-to-EBITDA too high?
Nippon Shinyaku Co's current EV-to-EBITDA of 3.77 is 75% below median its 10-year median of 14.89. Over the past 10 years, this metric has ranged from a low of 3.41 to a high of 40.68. The Drug Manufacturers industry median EV-to-EBITDA is 13.33. Nippon Shinyaku Co's value of 3.77 is 71.7% below this industry median. Based on the distribution chart, Nippon Shinyaku Co ranks #55 out of 734 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Nippon Shinyaku Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nippon Shinyaku Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Nippon Shinyaku Co ranks #55 out of 734 companies for EV-to-EBITDA. This places Nippon Shinyaku Co in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.33. Nippon Shinyaku Co's value of 3.77 is 71.7% below this benchmark. Historically, Nippon Shinyaku Co's own EV-to-EBITDA has ranged from 3.41 to 40.68 over the past decade. While the company's 10-year median is 14.89 vs. the industry median of 13.33, Nippon Shinyaku Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nippon Shinyaku Co's current EV-to-EBITDA of 3.77 is 71.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nippon Shinyaku Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nippon Shinyaku Co's current EV-to-EBITDA is 3.77, which is 75% below median its own 10-year median of 14.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nippon Shinyaku Co stock overvalued right now?
Based on GuruFocus' analysis, Nippon Shinyaku Co (TSE:4516) is currently considered Modestly Undervalued. The stock's GF Value™ is 円4,635.96, compared to a current price of 円3,640.00 — trading 21.5% below its estimated fair value. The current EV-to-EBITDA is 3.77, which is 75% below median its 10-year median of 14.89 and 71.7% below the Drug Manufacturers industry median of 13.33. Nippon Shinyaku Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Nippon Shinyaku Co (TSE:4516), the current EV-to-EBITDA is 3.77 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nippon Shinyaku Co (TSE:4516) Overvalued in 2026?
Based on GuruFocus' analysis, Nippon Shinyaku Co stock appears to be undervalued.
The current stock price of 円3,640.00 is trading 21.5% below its estimated GF Value™ of 円4,635.96.
GuruFocus considers Nippon Shinyaku Co to be Modestly Undervalued.
Key valuation signals for TSE:4516:
EV-to-EBITDA: 3.77 (75% below median its 10-year median of 14.89)
GF Value™: 円4,635.96 vs. price of 円3,640.00 (21.5% below fair value)
Industry Position: 71.7% below the Drug Manufacturers median (#55 of 734)
No single metric tells the full story. See the TSE:4516 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nippon Shinyaku Co Ltd is engaged in the pharmaceuticals and functional food businesses. The Pharmaceuticals Business develops and sells treatments for urological disorders, blood cancer, rare and intractable diseases, and gynecological conditions. The Functional Food Business produces and sells health food ingredients, quality-stabilizing preservatives, protein preparations, and supplements. It generates the majority of its revenue from the Pharmaceuticals segment.
79GF Score
Get the complete analysis for TSE:4516
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4516 has been successfully added to your 
